Epigenetic modifications affect the differentiation of T cell subsets and the pathogenesis of autoimmune diseases, but many mechanisms of epigenetic regulation of T cell differentiation are unclear. Here we show reduced expression of the transcription factor RFX1 in CD4 + T cells from patients with systemic lupus erythematosus, which leads to IL-17A overexpression through increased histone H3 acetylation and decreased DNA methylation and H3K9 tri-methylation. Conditional deletion of Rfx1 in mice exacerbates experimental autoimmune encephalomyelitis and pristane-induced lupus-like syndrome and increases induction of Th17 cells. In vitro, Rfx1 deficiency increases the differentiation of naive CD4 + T cells into Th17 cells, but this effect can be reversed by forced expression of Rfx1. Importantly, RFX1 functions downstream of STAT3 and phosphorylated STAT3 can inhibit RFX1 expression, highlighting a non-canonical pathway that regulates differentiation of Th17 cells. Collectively, our findings identify a unique role for RFX1 in Th17-related autoimmune diseases.
S ystemic lupus erythematosus (SLE) is a complex autoimmune disorder resulting in multi-organ destruction 1 . Autoantibody deposition and inflammatory cell infiltration in target organs such as kidneys and brain cause severe complications. Interleukin (IL)-17-producing CD4 + type 17 helper T (Th17) cells are defined by specific developmental and functional features that are distinct from those of Th1 and Th2 cells 2, 3 . Th17 cells primarily produce two members of the IL-17 family, IL-17A and IL-17F, which promote local chemokine production to recruit monocytes and neutrophils to sites of inflammation 4 . Aberrant Th17 cell differentiation, linked to increased Th17 cytokine production, is an important contributor to SLE pathogenesis 5 .
Epigenetic factors have a pivotal function in the pathogenesis of SLE 1 . DNA hypomethylation, increases in histone acetylation, and decreases in histone 3 lysine 9 (H3K9) and lysine 27 (H3K27) contribute to the overexpression of several autoimmune-related genes, such as CD70 and CD11a, which leads to the autoreactivation of T cells in SLE [6] [7] [8] [9] [10] . Epigenetic modifications are mediated by transcription factors in T cell subset differentiation [11] [12] [13] ; the transcription factor Etv5 recruits histone-modifying enzymes to the Il17a-Il17f locus, resulting in increased active histone marks and decreased repressive histone marks, thereby promoting IL-17A and IL-17F expression and Th17 differentiation 14 . Also, cAMP-responsive element modulator α (CREMα) protein induces IL-17A expression and mediates histone acetylation and DNA methylation at the IL17A gene locus through the recruitment of histone deacetylase 1 (HDAC1) and DNA methyltransferase 3a (DNMT3a) in patients with SLE 15 .
Our previous studies identified a decrease in transcription factor RFX1 expression in CD4 + T cells from SLE patients 16 . RFX1 is a member of the regulatory factor X (RFX) family of transcription factors, which can bind X-box of the DNA sequence to regulate the expression of target genes 17 . RFX1 has a C-terminal repressive region, an overlapping dimerization domain, and an N-terminal activation domain and is able to activate or repress target gene transcription depending on the cellular context 18 . RFX1 has an important function in brain tumors and sensorineural hearing loss 19, 20 . However, its function in immune cells and the immune response is unclear. Our previous studies showed that RFX1 regulates the immune-related genes CD11a and CD70 by affecting the epigenetic modifications of the two genes' loci in CD4 + T cells and that downregulation of RFX1 in CD4 + T cells contributes to the autoimmune response of SLE patients 16, 21 .
In this study, we investigate the function of RFX1 in aberrant Th17 differentiation in SLE patients. Our results indicate that RFX1 can repress IL-17A gene expression, and its deficiency contributes to increased IL-17 production and Th17 differentiation in patients with SLE. Rfx1 conditional deletion in mice exacerbates experimental autoimmune encephalomyelitis (EAE) and pristane-induced lupus-like mice models. We also show that downregulation of RFX1 causes increased histone acetylation and decreased histone 3 lysine 9 (H3K9) tri-methylation and DNA demethylation in the IL17A locus, thereby leading to overexpression of IL-17A and increasing Th17 cell differentiation. In addition, RFX1 functions downstream of signal transducer and activator of transcription factor 3 (STAT3) and IL-6-induced STAT3 activation can reduce the expression of RFX1. These data support a role for RFX1 deficiency in the pathogenesis of SLE, by mediating aberrant Th17 differentiation induced by IL-6 in the inflammatory environment.
Results
RFX1 expression is decreased in SLE CD4 + T cells. Our previous studies have shown that the expression and activity levels of RFX1 are decreased in CD4 + T cells from patients with SLE compared with healthy controls 16 . To gain a better understanding of the role that RFX1 plays in Th17 cell differentiation, we measured the mRNA and protein expression levels of RFX1 and IL-17A in CD4 + T cells from a new cohort of SLE patients, including 23 active patients and 8 inactive patients, and 14 healthy controls. The mRNA and protein expression levels of RFX1 were significantly decreased in CD4 + T cells of inactive and active SLE patients compared with healthy controls (Fig. 1a-c) . By contrast, both IL-17A mRNA expression levels in CD4 + T cells and IL-17A protein levels in serum were significantly elevated in SLE patients compared with healthy controls (Fig. 1d, e ). Furthermore, we found that the mRNA and protein levels of RFX1 were inversely correlated with the mRNA and serum protein levels of IL-17A ( Fig. 1f, g) . In addition, we also measured the expression of other genes associated with Th17 cells; however, there were no significant changes in mRNA expression levels of IL-17F and RORC between SLE CD4 + T cells and healthy controls ( Fig. 1h, i) .
RFX1 inhibits IL-17A expression in CD4 + T cells. To determine whether RFX1 regulates IL-17A expression in CD4 + T cells, we isolated CD4 + T cells from healthy controls and transfected them with RFX1 small interfering RNAs (siRNAs) and negative control, along with stimulation from anti-CD3 and CD28 antibodies. RFX1 protein levels were decreased in CD4 + T cells transfected with two siRNAs compared with negative control siRNA. IL-17A mRNA and protein expression levels were significantly increased in CD4 + T cells with RFX1 knockdown compared with negative control ( Fig. 2a-c) . By contrast, we overexpressed exogenous RFX1 in SLE CD4 + T cells through transfection of an RFX1 expression plasmid. When RFX1 expression was increased in SLE CD4 + T cells, IL-17A mRNA and protein expression levels were significantly decreased compared with empty vector control ( Fig. 2d-f ). Altogether, these data show that RFX1 represses IL-17A expression, and RFX1 loss can lead to IL-17A overproduction in CD4 + T cells.
RFX1 regulates chromatin modifications in the IL17A locus. To investigate the mechanism of RFX1 regulation of IL-17A expression, we predicted the putative binding sites of RFX1 in the promoter region of the IL17A gene. According to the predictions of the Matinspector and TFBIND software 22, 23 , two binding sites for RFX1 were found in the~468-452 bp (Site 1) and~639-623 bp (Site 2) regions upstream of the transcription start site (TSS) of IL17A ( Fig. 3a ). To investigate whether RFX1 regulates IL17A expression at the transcriptional level, we performed luciferase assays using reporter constructs spanning Site 1 and Site 2 of the human IL17A promoter. Indeed, RFX1 overexpression resulted in significant downregulation of IL17A promoter activities in the wild-type (WT) reporter construct. Next, we mutated Site 1 and Site 2, both separately and together, in the WT IL17A reporter construct and noted that the promoter activity was still repressed with both the individual Site 1 and Site 2 mutant reporter constructs. When both sites were mutated, RFX1 did not alter the promoter activity. These results suggest that both sites are crucial for RFX1-mediated IL17A transcription in human CD4 + T cells ( Fig. 3b ). Moreover, we used biotin-tagged specific probes for Site 1 or Site 2 to perform an electrophoretic mobility shift assay (EMSA) with an RFX1-specific antibody. The results showed that RFX1 could bind to Site 1 and Site 2 in the IL17A promoter ( Fig. 3c ). We also addressed the in vivo relevance of RFX1 binding to the IL17A promoter by chromatin immunoprecipitation (ChIP) assays. We observed marked RFX1 binding in the region containing Site 1 and Site 2 in the IL17A promoter in CD4 + T cells of healthy subjects ( Fig. 3d ).
Our previous studies have shown that RFX1 regulates levels of DNA methylation, H3 acetylation (H3ac), and H3K9 trimethylation (H3K9me3) in the promoters of CD11a and CD70 in SLE CD4 + T cells 16, 21 . DNA methylation of the IL17A promoter has been shown to be decreased in CD4 + T cells of SLE patients compared with healthy controls 15 . To characterize RFX1 regulation of histone modifications in the IL17A promoter, we first compared the RFX1 binding level and the H3ac and H3K9me3 levels between SLE CD4 + T cells and healthy controls by ChIP-quantitative PCR (qPCR). Two primers spanning RFX1binding Site 1 or Site 2 and one distal primer were used to amplify the ChIP product ( Supplementary Fig. 1a ). The results showed that the H3ac level was higher and that the H3K9 me3 level and the RFX1-binding level were lower in CD4 + T cells of SLE patients compared with healthy controls, which suggests that the changed histone markers may be related to RFX1 binding in the IL17A promoter region in SLE CD4 + T cells ( Supplementary Fig. 1b-d ).
Furthermore, we measured the changes in H3ac, H3K9me3, and DNA methylation levels in the promoter of IL17A in CD4 + T cells transfected with RFX1-siRNA or an RFX1 expression plasmid. We found that the H3ac level was elevated while the H3K9me3 level and DNA methylation levels of several CG pairs within the IL17A promoter region were downregulated in normal CD4 + T cells transfected with RFX1-targeting siRNAs compared with negative control (Fig. 4a-c) . By contrast, we found that the H3ac level was downregulated and H3K9me3 level and DNA methylation levels of several CG pairs within the IL17A promoter region were elevated in SLE CD4 + T cells transfected with an RFX1 expression plasmid compared with empty control ( Fig. 4d-f ).
Our previous studies showed that RFX1 could recruit a repressor complex including DNMT1, HDAC1, and SUV39H1 proteins and that RFX1 downregulation could lead to decreased recruitment of DNMT1, HDAC1, and SUV39H1 to the promoters of CD11a and CD70 in SLE CD4 + T cells 16, 21 . Therefore, we determined whether RFX1 also modulates the enrichments of DNMT1, HDAC1, and SUV39H1 in the IL17A promoter in CD4 + T cells. ChIP-qPCR assays showed that the binding levels of all three proteins were decreased significantly when RFX1 was knocked down in normal CD4 + T cells ( Fig. 4g-i) , whereas the binding of all three proteins to the IL17A promoter was increased significantly when RFX1 was overexpressed in SLE CD4 + T cells ( Fig. 4j-l naive CD4 + T cells from human peripheral blood and induced Th17 cell differentiation under Th17-polarizing conditions. We found that the mRNA and protein levels of RFX1 were significantly downregulated in induced Th17 cells on days 3 and 5 compared with naive CD4 + T cells ( Supplementary Fig. 2a, b ). Furthermore, we transfected both an RFX1 expression plasmid and a blank control into naive CD4 + T cells and then induced Th17 differentiation under Th17-polarizing conditions. The a CD4 + T cells from healthy controls were transfected with negative control siRNA (NC), RFX1specific siRNA#1 or siRNA#2, along with anti-CD3 and -CD28 antibody stimulation. The RFX1 protein level was downregulated significantly in CD4 + T cells transfected with siRNA#1 or siRNA#2 compared with NC. Representative results of western blot analysis are shown in the left panel, and the quantification of three independent experiments is shown in the right panel. b mRNA expression levels of IL-17A in cells from three groups were quantified by RT-qPCR. c IL-17 protein levels in the supernatants of culture media of three groups were measured by ELISA. d CD4 + T cells from SLE patients were transfected with RFX1 expression plasmid or empty control plasmid. Representative results of western blot analysis are shown in the left panel and the quantification of three independent experiments is shown in the right panel. e mRNA expression levels of IL-17A in cells of two groups were quantified by RT-qPCR. f IL-17A protein levels in supernatants of culture media of two groups were measured by ELISA. Data are representative of three independent experiments (mean ± s.d.; n = 3). *P < 0.05 and **P < 0.01, compared between the indicated groups. P-values were determined using the two-tailed Student's t-test results of flow cytometric analysis indicated that the percentage of IL-17 + CD4 + T cells was decreased in cells transfected with the RFX1 expression plasmid compared with the blank control ( Supplementary Fig. 2c ). Previous studies have shown that the IL17A promoter is demethylated and the H3K27 tri-methylation level in the IL17A promoter is decreased in Th17 cells 24, 25 . Here we analyzed the enrichment of RFX1 and the levels of H3ac and H3K9me3 in the IL17A promoter in induced Th17 cells. ChIP-qPCR results showed that the binding of RFX1 was significantly decreased, along with increased H3ac level and decreased H3K9me3 level in the induced Th17 cells on day 5 compared with naive CD4 + T cells ( Supplementary Fig. 3a -c). However, no significant change was observed in H3K4m3 level ( Supplementary  Fig. 3d ).
To determine whether RFX1 downregulation in pathogenic CD4 + T cells is a functionally relevant regulator of the development of autoimmune inflammation, we used homologous recombination to generate mice with an Rfx1 allele flanked by loxP sites (floxed; Fig. 5a ). Mice with confirmed germline transmission were crossed with CD4-cre transgenic mice to generate a conditional knockout mouse model with Rfx1 expression deficit specifically in CD4 + T cells ( Fig. 5b and Supplementary Fig. 4 ). These mice remained healthy without any detectable immune-mediated pathology for at least 32 weeks. EAE is a typical Th17-related autoimmune disease modeled in mice [26] [27] [28] , and Rfx1 expression was decreased significantly in CD4 + T cells from EAE mice compared with wild type (WT) mice ( Supplementary Fig. 5 ). Therefore, EAE disease models in Rfx1-sufficient (Rfx1 f/f ) and Rfx1-deficient (Rfx1 f/f -cre) mice were induced by immunization with myelin oligodendrocyte glycoprotein (MOG35-55). Rfx1 f/f mice developed signs of EAE on day 12 and reached the peak of the disease on day 19 after immunization. By contrast, disease onset advanced and was significantly more severe in Rfx1 f/f -cre mice when quantified by clinical score or weight loss ( Fig. 5c, d Rfx1 interferon (IFN)-γ-producing cells and the production of IL-17A in serum 19 days after immunization. As predicted by our in vitro results, Rfx1 deficiency significantly increased the percentage of CD4 + IL-17A + T cells in the spleens and draining lymph nodes of immunized mice, as well as the production of IL-17A in serum, without affecting the production of IFN-γ ( Fig. 5e-g ). Independent histological analysis of spinal cords demonstrated significantly increased inflammation and demyelination in Rfx1 f/f -cre mice (Fig. 5h, i ). In addition, we isolated splenocytes from the spleen of Rfx1 f/f and Rfx1 f/f -cre mice immunized with MOG35-55 at day 19 and further cultured with MOG (30 μg) re-stimulation in vitro. After 3 days, IL-17A and IFN-γ concentrations in the supernatant were measured by enzyme-linked immunosorbent assays (ELISA). The results showed that IL-17A production was increased significantly in Rfx1 f/f -cre mice compared with Rfx1 f/f mice, whereas IFN-γ production was not significantly different between two groups ( Supplementary Fig. 6 ). This result further points to the importance of Rfx1 in the generation of Th17 cells and the production of IL-17.
To confirm that Rfx1 plays a role in Th17 cell differentiation, we isolated naive CD4 + T cells from Rfx1 f/f or Rfx1 f/f -cre mice and stimulated them under Th17-polarizing conditions. As shown in Fig. 6a , b, the absence of Rfx1 resulted in a significant increase in the percentage of IL-17-producing T cells on days 5 and 7. The significantly elevated mRNA expression levels of IL-17A, IL-17F, IL-23R, and Rorc also indicated increased Th17 cell differentiation in Rfx1-deficient mice compared with Rfx1sufficient mice ( Fig. 6c-f ). To expand these results, we transfected naive CD4 + T cells from Rfx1 f/f -cre mice with either an empty vector or an Rfx1 expression plasmid. This allowed us to evaluate Rfx1-deficient cells before and after Rfx1 reconstitution. Cells were then stimulated in Th17-polarizing conditions, and the frequency of IL-17A-producing cells was quantified by flow cytometry (Fig. 6g ). As expected, the absence of Rfx1 resulted in a significant increase in CD4 + IL-17A + T cells. However, the reconstitution of Rfx1 restored the inhibition of Th17 differentiation significantly ( Fig. 6h-k ).
Next we verified the regulation by Rfx1 of the chromatin modifications of Il17a in Rfx1-deficient mice and EAE mice. We isolated CD4 + T cells from the spleens of Rfx1 f/f and Rfx1 f/f -cre mice. After 24 h of activation with anti-CD3 and anti-CD28 antibodies, ChIP-qPCR and bisulfite sequencing PCR (BSP) was used to determine the binding of HDAC1, SUV39H1, and DNMT1 and the levels of H3ac, H3K9me3, and DNA methylation in the promoter region of the mouse Il17a (mIl17a) gene containing the RFX1-binding motif. As expected, the binding of HDAC1, SUV39H1, and DNMT1 in the mIl17a promoter was significantly decreased in Rfx1 f/f -cre mice compared with Rfx1 f/f mice, leading to an increased H3ac level and decreased H3K9me3 and DNA methylation levels in the mIl17a promoter (Supplementary Fig. 7 ). Similar changes in chromatin modifications were also observed in CD4 + T cells from EAE mice compared with WT mice ( Supplementary Fig. 8 IL-17A At the end of the observation period, urinalysis showed that Rfx1 f/f -cre mice had a higher proteinuria level compared to Rfx1 f/f control mice (Fig. 7a ). Hematoxylin and eosin (H&E) staining of kidney sections revealed that Rfx1 f/f -cre mice had a marked increase in pathological lesions of glomerulus compared to Rfx1 f/f control mice (Fig. 7b ). Immunostaining analysis revealed more deposition of immunoglobulin G (IgG) and complement 3 (C3) in the glomeruli of Rfx1 f/f -cre mice compared with that in Rfx1 f/f control mice (Fig. 7c, d) . Serum levels of anti-dsDNA antibody and IL-17A protein were also significantly increased in Rfx1 f/f -cre mice (Fig. 7e, f ). In addition, flow cytometry showed an increased percentage of CD4 + IL-17A + T cells in the spleen of Rfx1 f/f -cre mice compared to Rfx1 f/f control mice (Fig. 7g, h) . Collectively, Rfx1 deficiency promotes the development of lupus-like mice model and exacerbates renal damage.
RFX1 is a downstream of STAT3. To clarify if the Th17polarizing cytokines repress the expression of RFX1, we measured RFX1 expression in CD4 + T cells with transforming growth factor (TGF)-β, IL-6, IL-23, or IL-1β stimulation respectively. The mRNA and protein expression levels of RFX1 were significantly inhibited by IL-6 stimulation, but no significant change was induced by TGF-β, IL-23, or IL-1β alone (Fig. 8a, b ). Decreased RFX1 level was significantly restored by STAT3 inhibitor, indicating that IL-6-STAT3 signal is necessary for RFX1 repression under Th17-polarizing conditions (Fig. 8c, d ). In addition, we also found that RFX1 expression level was negatively correlated with serum C-reactive protein (CRP) level, a surrogate marker of IL-6 activity, in SLE patients with active arthritis ( Supplementary  Fig. 9 ).
To investigate the mechanism of RFX1 downregulation in CD4 + T cells of SLE patients, we also determined the effect of IL-6-STAT3 signaling on RFX1 expression in CD4 + T cells of SLE patients. We compared the phosphorylated STAT3 (pSTAT3) level between SLE patients and healthy controls. As expected, the pSTAT3 level was higher in CD4 + T cells of active and inactive SLE patients than in healthy controls ( Supplementary Fig. 10a ). RFX1 expression was upregulated in CD4 + T cells of SLE patients when STAT3 expression was knocked down with siRNA ( Fig. 8e and Supplementary Fig. 10b, c) . In addition, we found that RFX1 expression was repressed in normal CD4 + T cells transfected with a STAT3 expression plasmid under IL-6 stimulation (Supplementary Fig. 10d-f ).
Enhancer activity of the seventh intron of the RFX1 gene has been reported 29 Rfx1
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Rfx1 intron of the RFX1 gene was hypermethylated in glioma cell lines and tissues but not in normal brain tissue or lymphocytes 29 . We predicted three potential STAT3-binding sites in the seventh intron of the RFX1 gene ( Fig. 9a ). ChIP-qPCR analysis showed that the enrichment of pSTAT3 was increased in the seventh intron of the RFX1 gene in CD4 + T cells under IL-6 stimulation, but no significant change was observed without IL-6 stimulation (Fig. 9b ). Moreover, we constructed a luciferase reporter plasmid containing a DNA fragment with STAT3-binding sites (WT) or with mutant STAT3-binding sites, both separately and together (Mu). STAT3 overexpression repressed the luciferase activity in the WT reporter construct or Mu reporter construct with a mutant signal site. However, the repression could be removed when all three sites were mutated simultaneously (Fig. 9c ). In addition, we found that the luciferase activity was lower in CD4 + T cells under IL-6 stimulation without or with STAT3 overexpression compared with negative control or empty vector control (Fig. 9d, e ). These data indicated that IL-6-induced STAT3 phosphorylation represses RFX1 expression through reducing the enhancer activity of the seventh intron of the RFX1 gene in CD4 + T cells. A previous study indicated that STAT3 can repress gene transcription by regulating chromatin modification through the recruitment of HDAC1 and DNMT1 30, 31 . To determine whether IL-6-STAT3 signaling has an effect on the chromatin conformation in the regulatory region of the RFX1 gene, we measured the DNA methylation status and histone modification of the seventh intron of the RFX1 gene. ChIP-qPCR results showed that IL-6 stimulation significantly reduced the H3 and H4 acetylation levels in the seventh intron of the RFX1 gene in CD4 + T cells (Fig. 9f ). As the methylation of CpG island located in the seventh intron of the RFX1 gene has an effect on the enhancer activity of the seventh intron, we measured the methylation level of CpG island in the seventh intron of the RFX1 gene and found that IL-6 stimulation elevated the methylation level in CD4 + T cells (Fig. 9g ). In addition, decreased H3 acetylation and DNA hypermethylation in the seventh intron of the RFX1 gene were also observed in SLE CD4 + T cells compared with healthy controls ( Supplementary Fig. 11 ). These data suggest that RFX1 downregulation is due to heterochromatin modifications induced by IL-6 stimulation in CD4 + T cells of SLE patients.
Discussion
Transcription factor-mediated epigenetic modifications regulate the spatiotemporal expression of genes in the development and differentiation of cells, as well as in the occurrence and progression of diseases 32 . Our previous study was the first to find a role for transcription factor RFX1 in the pathogenesis of SLE. RFX1 binds to the promoter regions of the CD11a and CD70 genes and forms a protein complex via the recruitment of HDAC1, DNMT1, and SUV39H1 to regulate the histone acetylation and methylation and DNA methylation of the CD11a and CD70 promoters in CD4 + T cells. The downregulation of RFX1 leads to the overexpression of CD11a and CD70 in SLE CD4 + T cells, which induces the increased reactivity of T cells 16, 21 . In the present study, we found that RFX1 expression was significantly negatively correlated with the expression of IL17A, as well as CD11a and CD70 expression, in CD4 + T cells of patients with SLE.
Recently, a growing body of evidence has supported the role of the effector cytokine IL-17A and Th17 cells in the pathogenesis of SLE 33 . It has been noted that patients with SLE, including those with new-onset disease, display increased serum or plasma levels of IL-17A, have an expansion of IL-17-producing T cells in the peripheral blood, and an infiltration of Th17 cells in the target organs, including the kidneys 34, 35 . Additionally, increased production of IL-17A correlates with disease activity in patients with SLE 5 . Here we demonstrated an important novel role for RFX1 in the regulation of the increased IL-17A expression in CD4 + T cells of patients with SLE, as well as in the differentiation of Th17 cells and the development of the IL-17-related autoimmune diseases EAE and lupus in mice. We provide evidence demonstrating that downregulation of RFX1 contributes to IL-17A overexpression and promotes IL-17A-producing T cell differentiation in SLE patients.
Here we present evidence that RFX1 is a negative regulatory factor in Th17 differentiation and autoimmune diseases. The expression of Th17-related genes such as IL-17A, IL-17F, IL-23R, and Rorc was increased in induced Th17 cells with Rfx1 deficiency, suggesting that differentiation of Th17 cells was promoted by the loss of Rfx1 under Th17-polarizing conditions. Moreover, lack of Rfx1 increased EAE clinical and histopathologic severity scores, as well as the frequency of peripheral IL-17A-producing cells. T cells from the spleens and draining lymph nodes of Rfx1deficient mice displayed no significant changes in IFN-γ production, but did have an overproduction of IL-17A, highlighting a predominant inhibitory effect of Rfx1 on Th17 differentiation. In addition, we also induced lupus-like mice model by intraperitoneal injection of pristane in Rfx1-deficient mice. Rfx1 deficiency increased the serum levels of anti-dsDNA antibody and IL-17A protein. Importantly, the more severe lupus-like kidney damage and deposition of IgG and C3 in kidney were observed in mice with Rfx1 deficiency. These results underscore the importance of RFX1 in the differentiation of Th17 cells and the pathogenesis of autoimmune diseases. Of interest, we found that IL-17F and RORC expression had a somewhat small reduction, but no significant difference, in CD4 + T cells of SLE patients 0  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28 Relative luciferase activity Relative luciferase activity STAT3-binding sites e Fig. 9 The IL-6-STAT3 pathway regulates epigenetic modifications of the RFX1 locus. a Genome location of the RFX1 locus and the STAT3-binding sites in intron 7 of the RFX1 gene. b ChIP-qPCR assay of pSTAT3 binding in intron 7 of RFX1 in CD4 + T cells with or without IL-6 stimulation. Primer 1 and Primer 2 were used to amplify the fragment containing STAT3-binding sites. c Luciferase reporter assay analysis of STAT3 regulation on the enhancer activity of intron 7 in 293T cells transfected with STAT3 expression vector (STAT3-over) or empty expression vector (EV). A, B, and C represent the STAT3-binding sites in intron 7. d Luciferase reporter assay analysis of the enhancer activity of intron 7 in CD4 + T cells with IL-6 stimulation and negative control. e Luciferase reporter assay analysis of the enhancer activity of intron 7 in CD4 + T cells with IL-6 stimulation transfected with STAT3 expression vector (STAT3-over) or empty expression vector (EV). f ChIP-qPCR analysis of H3 acetylation level and H4 acetylation level of intron 7 of the RFX1 gene in CD4 + T cells with or without IL-6 stimulation. g BSP analysis of the DNA methylation level of CpG island in intron 7 of the RFX1 gene in CD4 + T cells with or without IL-6 stimulation. The left panel shows the methylation level of each CpG site, and the right panel shows the mean methylation level of all 30 CpG sites in the CpG island. Data are representative of three independent experiments (mean ± s.d.; n = 3). *P < 0.05, **P < 0.01, compared between the indicated groups. n.s., not significant. P-values were determined using two-tailed Student's t-tests compared with normal controls, which is discrepant with the increased IL-17F and Rorc expression in the induced Th17 cells from mice with Rfx1 deficiency. The results may be due to more complicated regulatory mechanism of IL-17F expression in CD4 + T cells of SLE patients, which is different from the mechanism under Th17-polarizing conditions. DNA methylation and histone modifications, such as acetylation and methylation, play an important role in regulating gene expression through affecting the genomic accessibility of transcription factors 36 . It has been reported that the IL17A gene in human T cells from SLE patients and Th17 cells is subject to epigenetic remodeling at various levels, including DNA hypomethylation and reduced H3K27 tri-methylation in the promoter region of the IL17A gene 15, 37, 38 . In this study, we identified increased H3 acetylation (euchromatin) and decreased H3K9 trimethylation (heterochromatin) in the promoter of the IL17A gene in SLE CD4 + T cells compared with healthy controls and in induced Th17 cells compared with naive CD4 + T cells. In addition, we demonstrated that the downregulation of transcription factor RFX1 caused the DNA hypomethylation, the increased H3 acetylation, and the decreased H3K9 tri-methylation through the reduced recruitment of HDAC1, SUV39H1, and DNMT1 to the promoter region of IL17A in SLE CD4 + T cells. The epigenetic regulation of the Il17a gene was also confirmed in CD4 + T cells from mice deficient in Rfx1. The level of H3 acetylation was increased, while the levels of H3K9 tri-methylation and DNA methylation were decreased in the Il17a locus; meanwhile, the recruitment of HDAC1, SUV39H1, and DNMT1 was reduced significantly. Although the global DNA hypomethylation and aberrant histone modifications in the chromatin of CD4 + T cells have been identified in SLE patients 39 , the site-specific epigenetic modifications mediated by transcription factor RFX1 in IL17A, CD11a, and CD70 loci 16, 21 facilitated the characterization of altered epigenetic regulation occurring in the chromatin of CD4 + T cells, leading to the activation and inactivation of gene transcription. In fact, transcription factor-mediated aberrant epigenetic modifications in SLE have been reported in a previous study 15, 40 . For example, CREM interacts with DNMT3a, which mediates de novo CpG-DNA methylation, and facilitates DNMT3a recruitment to the CRE site of the human IL2 promoter, thereby repressing the transcription of the IL2 gene 40 .
Th17 differentiation requires the presence of IL-6 and its signal transduction partner STAT3 41 . Our findings provide evidence that RFX1 is a downstream partner of the IL-6/STAT3 signaling pathway. Moreover, reduction of RFX1 during Th17 differentiation is independent of TGF-β, IL-1β, and IL-23, as RFX1 expression was downregulated significantly in CD4 + T cells with IL-6 stimulation alone, which could be restored in the presence of STAT3 inhibitors. STAT3, activated by IL-6 and IL-23, is an essential regulator of lineage commitment of Th17 cells through the activation of RORC transcription by binding to the regulatory region 42 . By contrast, STAT3 can also repress gene transcription in different cell environments. Yeh et al. revealed that NR4A3 promoter binding by STAT3 might repress its transcription by promoter DNA methylation in gastric cancer 43 . Yang et al. found that STAT3 bound to the promoter region of Usp7 and inhibited its activity through the recruitment of HDAC1 31 . Here our data also demonstrated that the reduction of RFX1 in CD4 + T cells stimulated with IL-6 was due to the decreased enhancer activity of intron 7 of the RFX1 gene induced by the increased phosphorylated STAT3 protein, which binds intron 7 of the RFX1 gene to cause decreases in histone acetylation and increases in DNA methylation. These data revealed that the IL-6-STAT3 signaling pathway can induce Th17 differentiation through repressing RFX1 expression, suggesting a noncanonical regulatory pathway in CD4 + T cells, and further demonstrating the important role of transcription factors and their site-specific epigenetic regulation in the pathogenesis of SLE.
In conclusion, we have provided evidence that RFX1 downregulation contributes to the increased IL-17A expression and Th17 cell differentiation in the CD4 + T cells of patients with SLE, as well as promotes the pathologic changes of autoimmune diseases including EAE and lupus-like mice models. RFX1 inhibits IL-17A expression, which is largely dependent on epigenetic regulation. As depicted in Fig. 10 , in normal CD4 + T cells, RFX1 recruits HDAC1, SUV39H1, and DNMT1 to the promoter region of IL17A and decreases the histone acetylation and increases the H3K9 tri-methylation and promoter hypermethylation. This results in a heterochromatin state in the promoter region of IL17A, leading to inactivation of IL17A transcription. However, in CD4 + T cells of patients with SLE, RFX1 expression is inhibited by IL-6-induced pSTAT3 through the regulation of the histone acetylation and DNA methylation status of intron 7 of RFX1, and RFX1 downregulation relieves the epigenetic restraint of the promoter region of IL17A, leading to the overproduction of IL-17 in SLE patients. These data demonstrate the important role of RFX1 in Th17 cells differentiation and the pathogenesis of SLE.
Methods SLE patients. This study was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University, China, and written informed consent was obtained from all participants. SLE patients were recruited from outpatient dermatology clinics and in-patient wards. All patients fulfilled at least four of the SLE classification criteria of the American College of Rheumatology 44 . Lupus disease activity was assessed using the SLE Disease Activity Index (SLEDAI) 45 . Age-, sex-, and ethnicity-matched healthy individuals were enrolled as controls. Peripheral venous blood was collected from each patient and control subject and preserved with heparin. CD4 + T cells were isolated by positive selection using CD4 beads, according to protocols provided by the manufacturer (Miltenyi); purity was generally >95%. Basic demographic information, serum CRP levels, and SLEDAI scores at the time of blood sample collection and enrollment in our study for each patient are presented in Supplementary Table 1 .
Transfection of overexpression plasmid or siRNA. Purified CD4 + T cells were cultured in 24-well plates (1 × 10 6 cells ml −1 ) and stimulated with plate-bound anti-CD3 antibody (5 μg ml −1 , Calbiochem, clone: UCHT1), followed by the addition of soluble anti-CD28 antibody (2 μg ml −1 , Calbiochem, clone: ANC28.1/5D10) and incubated at 37°C for 6 h. CD4 + T cells were transfected with plasmid or siRNA using a Human T-cell Nucleofector Kit and an Amaxa nucleofector (Lonza). Briefly, CD4 + T cells were harvested, resuspended in 100 μl human T-cell nucleofector solution, and RFX1 expression plasmid pSG5-RFX1 16 Decreased RFX1 leads to the loss of recruitment of DNMT1, HDAC1, and SUV39H1 to the promoter of IL17A gene, which decreases the DNA methylation and histone H3K9 tri-methylation and increases the histone acetylation, thereby inducing the activation of IL17A gene transcription expression plasmid (Fulengen), RFX1-siRNAs (HSS109204 and HSS109206, Thermo Fisher Scientific), or STAT3-siRNA (HSS181509, Thermo Fisher Scientific) was added. Cells were electrotransfected using the nucleofector program V-024 in the Amaxa nucleofector and cultured in human T cell culture medium 16 .
RNA isolation and qPCR. Total RNA was extracted from CD4 + T cells using Trizol reagent (Thermo Fisher Scientific). Extracted samples were reversetranscribed with a PrimeScript ® RT Reagent Kit with gDNA Eraser (TaKaRa) using 1 μg of total RNA according to the manufacturer's instructions. The reaction mixture contained 2 μl cDNA, 10 μl SYBR Premix Ex TaqTM (TaKaRa), and 400 nM sense and antisense primers in a final volume of 20 μl. Transcripts were measured using a LightCycler® 96 System (Roche). The level of gene expression was calculated using the comparative CT method. β-Actin was also amplified and used as a loading control. All primer sequences are listed in Supplementary Table 2 .
Western blotting. CD4 + T cells were lysed and proteins were extracted and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 8% polyacrylamide gels. Proteins were then transferred onto polyvinylidene difluoride membranes (Millipore). Membranes were blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) buffer and immunoblotted with antibodies against RFX1 (Santa Cruz, clone: I-19, 1:500), pSTAT3 (Tyr705, clone: D3A7, 1:2000) or β-actin (Santa Cruz, sc-130300, 1:2000). Band intensity was quantified using ImageQuant TM LAS 4000 mini (GE-Healthcare). Uncropped original scans of immunoblots were provided in Supplementary Fig. 12 .
ELISA. The following ELISA kits were used: Human and mouse IL-17 or IFNgamma Quantikine ELISA Kits (R&D Systems) and anti-dsDNA antibody ELISA Kit (Alpha diagnostic). All procedures were performed according to the manufacturer's instructions.
In vitro human Th17 cells differentiation. Peripheral blood mononuclear cells (PBMCs) were separated from the peripheral blood of healthy individuals by density gradient centrifugation (GE Healthcare). Naive T cells were isolated by negative selection using Miltenyi beads according to the manufacturer's instructions (Miltenyi Biotech). Purified naive CD4 + T cells were stimulated with platebound anti-CD3 (5 μg ml −1 , Calbiochem, clone: UCHT1) and anti-CD28 (2 μg ml −1 , Calbiochem, clone: ANC28.1/5D10) for 3 or 5 days under Th17-polarizing conditions: TGF-β (5 ng ml −1 , PeproTech), IL-6 (10 ng ml −1 , PeproTech), IL-1β (10 ng ml −1 , PeproTech), IL-23 (20 ng ml −1 , PeproTech), anti-IFN-γ (10 μg ml −1 , eBioscience, clone: MD-1), and anti-IL-4 (10 μg ml −1 , eBioscience, clone: MP4-25D2) for Th17. Cell culture was performed in 24-well plates in a total volume of 1 ml well −1 of culture medium with 1 × 10 6 naive CD4 + T cells. The medium was refreshed on day 3.
In vitro mouse Th17 cells differentiation. Naive CD4 + T cells were purified from pooled single-cell suspensions of spleens using a mouse naive CD4 + T Cell Isolation Kit II (Miltenyi) and were stimulated with plate-bound anti-CD3 (5 μg ml −1 , eBioscience, clone: 145-2C11) and anti-CD28 (2 μg ml −1 , eBioscience, clone: 37.51) for 3, 5, and 7 days under Th17-polarizing conditions. For Th17 cell differentiation, naive CD4 + T cells were stimulated with TGF-β (2 ng ml −1 , PeproTech), IL-6 (30 ng ml −1 , PeproTech), IL-1β (10 ng ml −1 , PeproTech), and IL-23 (20 ng ml −1 , R&D Systems) in the presence of anti-IFN-γ (10 μg ml −1 , eBioscience, clone: R4-6A2) and anti-IL-4 (10 μg ml −1 , eBioscience, clone: 11B11). Cell culture was performed in 24-well plates in a total volume of 1 ml well −1 of culture medium with 1 × 10 6 naive CD4 + T cells. The medium was refreshed on day 3.
Flow cytometry. The expression of surface markers and intracellular molecules was evaluated by flow cytometry with a FACS Canto II (BD Biosciences), and data were analyzed by the Flowjo software (Tree Star). The following antibodies were used for flow cytometry: anti-human CD4-FITC (clone: RPA-T4), IFN-γ-Percp-Cy5.5 (clone: B27), and IL-17A-PE (clone: N49-653) were purchased from BD Biosciences. Anti-mouse CD4-FITC (clone: RM4-5) was purchased from BioLegend. Anti-mouse IFN-γ-percp-Cy5.5 (clone: XMG1.2), IL-17A-PE and IL-17Apercp-Cy5.5 (clone: TC11-18H10) were purchased from BD Biosciences. To detect the expression of IFN-g and IL-17A, the cells were treated with ionomycin (750 ng ml −1 , Sigma), phorbol 12-myristate 13-acetate (200 ng ml −1 , Sigma), and BD GolgiPlug (BD Biosciences) for 4-6 h in a cell incubator (37°C, 5% CO 2 ). Surface marker staining was done at 4°C in the dark for 30 min. All flow cytometric gating strategies are shown in Supplementary Fig. 13 .
Luciferase reporter constructs. To generate the human IL17A promoter luciferase reporter construct, the proximal 662 bp of the human IL17A promoter (from -662 bp to -1 bp upstream of TSS) was PCR-amplified from genomic DNA of human CD4 + T cells and cloned into a luciferase vector pGL3-Basic (Promega) using the following primers: Forward, 5′-TTGGTACCTTTCAATTCCTTCCT-CAAAACACCA-3′, and Reverse, 5′-TTCTCGAGTATGAGATGGA-CAAAATGTAGCGCT-3′, with attached restriction sites for Kpn I and Xho I (underlined). The DNA fragments (from -662 bp to -1 bp upstream of TSS) with loss of binding Site 1 and/or binding Site 2 were synthesized directly and cloned into the pGL3-Basic vector.
To generate the human RFX1 enhancer luciferase reporter construct, intron 7 containing three STAT3 binding sites of the RFX1 gene was PCR-amplified from genomic DNA of human CD4 + T cells and cloned into the luciferase vector pGL3promoter (Promega) using the following primers: Forward, 5′-CGGGGTACCGAGGGAAATGCCTCTGTGAG-3′, and Reverse, 5′-CCGCTCGAGAGCTACAGAAAGGGCCTCAG-3′, with attached restriction sites for Kpn I and Xho I (underlined). The Mut Express II Fast Mutagenesis Kit V2 (Vazyme) was used for site-directed mutagenesis based on the template of the WT RFX1 enhancer luciferase reporter construct. The primers used to amplify the sitedirected mutant plasmids are listed in Supplementary Table 3 . The luciferase reporter construct with all three sites mutated was amplified based on the template of the construct with two mutant sites. All procedures were performed according to the manufacturer's instructions. All plasmid DNA preparations were carried out with DNA purification kits (Qiagen) and sequence-verified.
Luciferase assay. The day before transfection, 5 × 10 4 Jurkat cells (ATCC, TIB-152™) were seeded into 24-well culture plates in fresh medium. Cells were transfected with 500 ng of the IL17A promoter-luciferase reporter plasmid and 1 μg RFX1 expression plasmid or empty plasmid using the Amaxa Human T-cell Nucleofector Kit (Lonza) and an Amaxa Nucleofector II device (program U014; Lonza). HEK293T cells (ATCC, CRL-11268™) were transfected with 500 ng of RFX1 intron 7-luciferase reporter plasmid and 1 μg STAT3 expression plasmid or empty plasmid using Lipofectamine 2000. To detect the effect of IL-6 on the enhancer activity of intron 7, IL-6 (10 ng ml −1 ) was added into culture medium of CD4 + T cells after 24 h of transfection of the WT human RFX1 enhancer luciferase reporter construct. Each reporter experiment included 100 ng of renilla luciferase construct as an internal control. Forty-eight hours after transfection, cells were collected and lysed, and luciferase activity was quantified using the Promega Dual Luciferase Assay System (Promega) following the manufacturer's instructions.
Electrophoretic mobility shift assays. For EMSAs, two double-stranded DNA probes harboring two RFX1 binding sites of the human IL17A promoter were synthesized with biotin-labeled 3′ ends (Binding site 1: 5′-CAC-CAAGTTGCTTGGTAGCATGCAGGGTTGGAACATGCC-3′; Binding site 2: 5′-TTATATGATGGGAACTTGAGTAGTTTCCGGAATTGTCTCCACAA-CACCTGG-3′). Binding reactions were performed according to the manufacturer's instruction with a LightShift™ Chemiluminescent EMSA Kit (Thermo Scientific). Briefly, biotin end-labeled DNA containing the binding site was incubated with nuclear extract. This reaction was then subjected to gel electrophoresis on a native polyacrylamide gel and transferred to a nylon membrane. The biotin end-labeled DNA was detected using the Streptavidin-Horseradish Peroxidase Conjugate and the Chemiluminescent Substrate. For supershift assays, 2 μg of RFX1 antibody (Santa Cruz, Clone: I-19) was added to the binding reaction. Two hundred-fold molar excess of the cold unlabeled oligonucleotide was used for competition assays.
Chromatin immunoprecipitation assays. Anti-RFX1 antibody (Santa Cruz, Clone: I-19) used for ChIP assays was purchased from Santa Cruz. H3ac (cat. no. 39139), H3K4me3 (cat. no. 39915), and H3K9me3 (cat. no. 39765) antibodies were from Active Motif. Phosphorylated STAT3 antibody (clone: D3A7) was from CST. DNMT1 (cat. no. ab13537), HDAC1 (cat. no. ab7028), and SUV39H1 (cat. no. ab8898) were from Abcam. ChIP experiments were carried out with a ChIP Assay Kit (Millipore) according to the manufacturer's protocol. Briefly, 2 million cells were cross-linked with 1% formaldehyde, washed with cold phosphate-buffered saline, and lysed in buffer containing protease inhibitors (Roche). Cell lysates were sonicated to shear DNA and sedimented, and diluted supernatants were immunoprecipitated with the indicated antibodies. In all, 10% of the diluted supernatants were kept as "input" (input represents PCR amplification of the total sample). Realtime PCR primer sequences are shown in Supplementary Table 4 . The amount of immunoprecipitated DNA was subtracted from the amount of amplified DNA, which was bound by the nonspecific normal IgG and subsequently calculated relative to the respective input DNA.
BSP. Genomic DNA was isolated from CD4 + T cells using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's protocol. Bisulfite conversion was performed using the EZ DNA Methylation™ Kit (Zymo Research). The 264 bp fragment, including 7 CG pairs in the human IL17A promoter, the 421 bp fragment, including 7 CG pairs in the mouse Il17a promoter, and the 273 bp fragment, including 30 CG pairs in intron 7 of the RFX1 gene, were amplified by nested PCR and cloned into the pGEM-T vector (Promega). Ten independent clones were sequenced for each of the amplified fragments. Primers are listed in Supplementary  Table 5 .
Generation of Rfx1 f/f and Rfx1 f/f CD4-cre mice. All animal care protocols and experiments were reviewed and approved by the Animal Care and Use Committees of the Laboratory Animal Research Center at the Second Xiangya Medical School of Central South University. The Rfx1 locus (ENSMUSG00000031706, http://www. ensembl.org/index.html) is on chromosome 8 (Mus musculus), which includes 21
